Global Dabigatran Market 2023-2030

    In Stock

    Coming Soon




    The FDA has given its approval for Dabigatran it to lower your risk of getting a blood clot, which can be harmful if it forms in your legs or lungs. Deep vein thrombosis is the usual name for a blood clot that forms in your lower legs. And a pulmonary embolism is a blood clot in your lungs. Venous thromboembolisms are the collective name for these disorders.


    FDA-approved medication for persons with nonvalvular atrial fibrillation to reduce their risk of stroke and blood clots. The top chambers of your heart are beating irregularly. Nonvalvular indicates that the problem is not brought on by dysfunctional heart valves.


    Adults who have taken an anticoagulant in injection form for five to ten days should be treated for DVTs and PEs. Children aged 8 to 17 who have taken an anticoagulant in injection form for at least five days should be treated for VTEs.


    Reduce the risk of DVTs, PEs, and VTEs in adults, as well as in kids aged 8 to 17 who have already had therapy for these conditions. Adults with hip replacements should avoid DVTs and PEs. drug information. The primary medication in Pradaxa is dabigatran, a member of the group of medications known as direct thrombin inhibitors.


    One example of an anticoagulant is Pradaxa. You ingest the capsule form of Pradaxa. The recommended dosage is one or two times per day. Dangerous side effects of the medication include uncontrolled bleeding.


    The medication was promoted as being simple to take and not needing to be monitored. Yet, internal business records revealed that staff members attempted to suppress a research report. They worried that it would result in a demand for a blood test.




    infographic: Dabigatran Market , Dabigatran Market Size, Dabigatran Market Trends, Dabigatran Market Forecast, Dabigatran Market Risks, Dabigatran Market Report, Dabigatran Market Share


    The Global Dabigatran Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    The U.S. Food and Drug Administration has tentatively approved Breckenridge Pharmaceutical, Inc.’s Abbreviated New Drug launched Application for Dabigatran Etexilate Capsules.


    An external contract manufacturing company developed this product. The three strengths that are typical of the brand are present in Breckenridge: 75mg, 110mg, and 150mg.  





    1. How many  Dabigatran are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global  Dabigatran and key vendor selection criteria
    3. Where is the  Dabigatran manufactured? What is the average margin per unit?
    4. Market share of Global  Dabigatran market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global  Dabigatran in-house
    6. key predictions for next 5 years in Global  Dabigatran market
    7. Average B-2-B  Dabigatran market price in all segments
    8. Latest trends in  Dabigatran market, by every market segment
    9. The market size (both volume and value) of the  Dabigatran market in 2023-2030 and every year in between?
    10. Production breakup of  Dabigatran market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop